PLSH — Panacea Life Sciences Holdings Cashflow Statement
0.000.00%
- $1.11m
- $13.15m
- $2.38m
Annual cashflow statement for Panacea Life Sciences Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K/A | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -10.2 | -10.9 | -4.78 | -9.14 | -8.02 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 5.28 | 7.96 | -1.51 | 3.45 | 1.74 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -1.7 | 1.46 | 0.632 | 1.56 | 3.03 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -5.75 | -0.7 | -3.92 | -2.4 | -1.52 |
Capital Expenditures | -0.541 | 0 | -0.163 | -0.244 | -0.065 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -1.5 | 0 | 0.685 | 0.047 | 0 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Cash from Investing Activities | -2.04 | 0 | 0.523 | -0.197 | -0.065 |
Financing Cash Flow Items | 0.242 | 0.096 | — | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 7.8 | 0.706 | 3.33 | 2.58 | 1.68 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.016 | 0.007 | -0.065 | -0.013 | 0.094 |